» Articles » PMID: 22570464

Probiotics for the Prevention and Treatment of Antibiotic-associated Diarrhea: a Systematic Review and Meta-analysis

Overview
Journal JAMA
Specialty General Medicine
Date 2012 May 10
PMID 22570464
Citations 272
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Probiotics are live microorganisms intended to confer a health benefit when consumed. One condition for which probiotics have been advocated is the diarrhea that is a common adverse effect of antibiotic use.

Objective: To evaluate the evidence for probiotic use in the prevention and treatment of antibiotic-associated diarrhea (AAD).

Data Sources: Twelve electronic databases were searched (DARE, Cochrane Library of Systematic Reviews, CENTRAL, PubMed, EMBASE, CINAHL, AMED, MANTIS, TOXLINE, ToxFILE, NTIS, and AGRICOLA) and references of included studies and reviews were screened from database inception to February 2012, without language restriction.

Study Selection: Two independent reviewers identified parallel randomized controlled trials (RCTs) of probiotics (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and/or Bacillus) for the prevention or treatment of AAD.

Data Extraction: Two independent reviewers extracted the data and assessed trial quality.

Results: A total of 82 RCTs met inclusion criteria. The majority used Lactobacillus-based interventions alone or in combination with other genera; strains were poorly documented. The pooled relative risk in a DerSimonian-Laird random-effects meta-analysis of 63 RCTs, which included 11 811 participants, indicated a statistically significant association of probiotic administration with reduction in AAD (relative risk, 0.58; 95% CI, 0.50 to 0.68; P < .001; I(2), 54%; [risk difference, -0.07; 95% CI, -0.10 to -0.05], [number needed to treat, 13; 95% CI, 10.3 to 19.1]) in trials reporting on the number of patients with AAD. This result was relatively insensitive to numerous subgroup analyses. However, there exists significant heterogeneity in pooled results and the evidence is insufficient to determine whether this association varies systematically by population, antibiotic characteristic, or probiotic preparation.

Conclusions: The pooled evidence suggests that probiotics are associated with a reduction in AAD. More research is needed to determine which probiotics are associated with the greatest efficacy and for which patients receiving which specific antibiotics.

Citing Articles

Pulmonary nontuberculous mycobacterial infections among women with cystic fibrosis and non-cystic fibrosis bronchiectasis.

Gross J, Jones M, Buige A, Prevots D, Kasperbauer S Ther Adv Respir Dis. 2025; 19:17534666251323181.

PMID: 40071337 PMC: 11898043. DOI: 10.1177/17534666251323181.


Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation.

Sun J, Song S, Liu J, Chen F, Li X, Wu G NPJ Biofilms Microbiomes. 2025; 11(1):43.

PMID: 40069181 PMC: 11897378. DOI: 10.1038/s41522-025-00678-x.


An update and overview of the various health-related benefits of probiotics: A focus on clinical trials demonstrating efficacy, tolerability and use in patients with impaired glucose tolerance and type 2 diabetes.

Toshimitsu T, Irie J Diabetes Obes Metab. 2025; 27 Suppl 1:15-22.

PMID: 39989436 PMC: 11894779. DOI: 10.1111/dom.16273.


Microbiota modifications in prehabilitation - the next step towards comprehensive preparation for surgery. The scoping review.

Loniewski I, Banasiewicz T, Sienko J, Skonieczna-Zydecka K, Stachowska E Prz Gastroenterol. 2025; 16(4):347-361.

PMID: 39810873 PMC: 11726224. DOI: 10.5114/pg.2024.145833.


Anti-inflammatory and anti-oxidative effect of pasterurised yoghurt in indomethacin induced gastric ulceration in male Wistar rats.

Ajayi O, Omolaso B, Omayone T, Adeniran A, Adu A, Olorunfemi O Heliyon. 2025; 10(24):e40770.

PMID: 39759379 PMC: 11698930. DOI: 10.1016/j.heliyon.2024.e40770.